TriSalus Life Sciences Inc
NASDAQ:TLSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (12.2), the stock would be worth $7.23 (70% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.2 | $4.26 |
0%
|
| 3-Year Average | 12.2 | $7.23 |
+70%
|
| 5-Year Average | 12.2 | $7.23 |
+70%
|
| Industry Average | 6 | $3.56 |
-17%
|
| Country Average | 6.5 | $3.86 |
-9%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| US |
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
261.6m USD | 7.2 | -3.7 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.7B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 2 198.6 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
99.6B ZAR | 13.1 | 10.3 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.3B USD | 0 | 38 074.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
57.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.3B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.3B EUR | 3.1 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
34.5B USD | 68.5 | -3 171.8 | |
| US |
Q
|
Qnity Electronics Inc
NYSE:Q
|
29.6B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.2 |
| Median | 6.5 |
| 70th Percentile | 10.6 |
| Max | 1 764 211.7 |
Other Multiples
TriSalus Life Sciences Inc
Glance View
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
